Clinical trials: Endocrine Disorder
Ovarian Cancer
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects…
- Trial name
- NCT05601752
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- USWM CT, LLC
Non-Small Cell Lung Cancer, Ovarian Cancer
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer
Study DNB4987g is a Phase I, multicenter, open label, dose-escalation study of DNIB0600A administered as a single agent by intravenous (IV) infusion every three weeks (q3w) to participants with non-squamous NSCLC or non-mucinous…
- Trial name
- NCT01363947
- Testing
- DNIB0600A
- Where
- 7 sites in United States, Spain
- Volunteers
- 87 people
- Sponsor
- Genentech, Inc.
Type 2 Diabetes Mellitus, Arteriosclerosis Obliterans
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
1. To evaluate the efficacy of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker 2. To evaluate the safety of Cilostazol and Probucol alone and in combination on atherosclerosis related…
- Trial name
- NCT00823849
- Testing
- Cilostazol, Probucol, Cilostazol+Probucol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Otsuka Beijing Research Institute
Diabetes Mellitus, Type 1
A Study in Adults With Type 1 Diabetes
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
- Trial name
- ELEMENT 1 (NCT01421147)
- Testing
- LY2963016, Lantus, Insulin Lispro
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
This study is an open-label, randomized, fed, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-393 in healthy subjects
- Trial name
- NCT04260438
- Testing
- CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Advanced Cancer, Gastric Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care.
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Trial name
- NCT04396821
- Testing
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
- Trial name
- NCT00885378
- Testing
- Saxagliptin plus metformin IR
- Where
- 41 sites in United States, Germany and 2 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients
This trial is conducted in Africa and Asia. The aim of the trial is to compare patient-adjusted versus physician-adjusted titration of BIAsp 30 combined with metformin in type 2 diabetes patients uncontrolled on NPH insulin.
- Trial name
- NCT01589653
- Testing
- biphasic insulin aspart 30
- Where
- 15 sites in Egypt, Indonesia and 4 more
- Volunteers
- 155 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type II
A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus
The purpose of the study is to determine if repeated daily doses of T0903131 (INT131) Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00952445
- Testing
- T0903131 Besylate
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- InteKrin Therapeutics, Inc.
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320021
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 80 people
- Sponsor
- BioStratum
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Diabetes Mellitus, Type 2
Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)
A study of patients with type 2 diabetes and inadequate glycemic control on two or more oral antihyperglycemic agents comparing adding insulin lispro mid mixture to the oral antihyperglycemic agents to adding insulin glargine to…
- Trial name
- IOOX (NCT00377858)
- Testing
- Insulin lispro mid mixture (MM), Insulin glargine
- Where
- 25 sites in Australia, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Eli Lilly and Company
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT03332576
- Testing
- DPX-Survivac, DPX-Survivac(Aqueous), Cyclophosphamide
- Where
- 3 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Obesity or Overweight, Type 2 Diabetes
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-4 (NCT07843485)
- Testing
- Petrelintide
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
Evaluation of Stendo Pulsating Suit on Microcirculation and Endothelial Function in Diabetic Patients
The action of one Stendo pulsating suit session will be evaluated on 16 type 2 diabetic patients referred on the diabetic consultations.
- Trial name
- Diabete_1 (NCT02293135)
- Testing
- Verum Stendo session on V1 and Phantom Stendo session on V2, Phantom Stendo session on V1 and Verum Stendo session on V2
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Stendo
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Diabetes Mellitus
A Study to Evaluate the Blood Glucose Regulation and Safety of PPB-R-203-02 Based Noodle Versus Commercially Available Wet Noodle in Patients With Diabetes
To evaluate the result of PPB-R-203-02 based noodle and commercially available wet noodle on blood glucose control in 24 patients with diabetes for 2 days.
- Trial name
- NCT01102452
- Testing
- Commercially Available Wet Noodle, PPB-R-203-02 Noodle
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Pharma Power Biotec Co., Ltd.
Breast Neoplasms, Lung Neoplasms
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture…
- Conditions
- Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
- Trial name
- NCT00243685
- Testing
- Laboratory Assay, Mick Assay
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pierian Biosciences
Xerostomia Due to Hyposecretion of Salivary Gland, Diabetes Mellitus, Type 2
The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II
In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with…
- Trial name
- NCT03452085
- Testing
- artificial saliva spray (AS), maritime throat spray (TT)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Certmedica International GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.